Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 9,051 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now directly owns 26,528 shares of the company's stock, valued at $595,553.60. This represents a 25.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Kiniksa Pharmaceuticals Trading Up 2.0 %
KNSA stock opened at $22.61 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1-year low of $16.56 and a 1-year high of $28.15. The firm has a market cap of $1.64 billion, a P/E ratio of -161.49 and a beta of 0.48. The business's 50 day moving average is $19.95 and its 200-day moving average is $22.22.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06). The company had revenue of $122.50 million during the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company's revenue for the quarter was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.35 earnings per share. Sell-side analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.
Analysts Set New Price Targets
Several equities analysts recently weighed in on KNSA shares. Citigroup started coverage on Kiniksa Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $40.00 price objective for the company. Wedbush restated an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $37.17.
View Our Latest Analysis on KNSA
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
A number of large investors have recently bought and sold shares of the business. Braidwell LP grew its position in Kiniksa Pharmaceuticals by 19.3% during the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Millennium Management LLC lifted its holdings in Kiniksa Pharmaceuticals by 50.9% during the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after buying an additional 263,146 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after purchasing an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 1.4% in the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock valued at $15,141,000 after purchasing an additional 10,209 shares during the period. 53.95% of the stock is currently owned by institutional investors.
About Kiniksa Pharmaceuticals
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
